GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

It stands out in a region where Amish farms and hills covered with second-growth red-oak woods, parks, and hiking trails ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

Think logos are tacky? No more. Fashion has shifted from giant Gs and Cs to quiet branding that lets men and women subtly ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...

The primary logo features the fan-favorite bear with the rolling Smoky Mountains. The Smokies script sits on top of the ...

In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, ...

AI-enhanced manufacturing applications are now being deployed around the world as a massive upgrade in efficiency.

GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.